Interview Questions for Arul Chinnaiyan, University of Michigan
Arul Chinnaiyan’s from University of Michigan and Michigan Medicine responses to interview questions from Tal Behar, Precision World Medicine Conference 1. Breaking the Gene Fusion Paradigm: Your discovery of the TMPRSS2-ERG gene fusion – now recognized as a defining molecular event in prostate cancer – broke new ground by revealing that gene fusions can drive common […]
Interview Questions for Jeff Balser, VUMC
Precision Medicine World Conference Jeff Balser Interview 1. AI / operations VUMC’s strategy is to use AI to scale as a means to grow while better controlling increases in staffing. In what areas are you focusing? Our approach is to focus on specific domains while developing standard platforms and processes to facilitate AI implementation […]
Interview Questions for Joe Petro, Microsoft Dragon
Joe Petro’s responses to interview questions from Tal Behar, Precision World Medicine Conference Q1. What impact is Dragon Copilot having today, and what outcomes are you prioritising for 2026?A1. Dragon Copilot gives clinicians time back and reduces cognitive burden—shifting focus from paperwork to patients.What began with physicians now increasingly supports nurses and radiologists. In 2026, […]
Interview Questions for Daniel De Carvalho
Daniel De Carvalho responses to interview questions from Tal Behar, Precision World Medicine Conference Daniel D. De Carvalho, PhDProfessor, University of Toronto; ALLAN SLAIGHT Senior Scientist, Princess Margaret Cancer Centre/University Health Network; Co-Founder and CSO, Adela Where does methylation add indispensable value in MRD vs mutation‑only approaches (e.g., low‑shedding tumors, tissue‑of‑origin context, earlier relapse […]
Interview Questions for Serge Saxonov, 10x Genomics
Serge Saxonov’s (10x Genomics) responses to interview questions from Tal Behar, Precision World Medicine Conference Q1. Single-cell and spatial assays are powering translational research but aren’t yet routine diagnostics. What’s the biggest barrier — scientific, regulatory, or cultural — to bringing these technologies into clinical use? The biggest barrier right now is clinical evidence. We […]
Interview Questions for Klaus Pantel
RE: I believe that a combination of these liquid biopsy approaches holds most promise for improving cancer screening and would also include non-ctDNA biomarkers such as circulating extracellular vesicles, proteins, metabolites, RNAs and tumor cells. Such a composite biomarker panel is currently evaluated for early pancreatic cancer screening in the EU Horizon consortium PANCAID (https://pancaid-project.eu; Lead-PI: K. Pantel). Challenges that must b
Interview Questions for Curtis P. Langlotz
Curtis P. Langlotz’s responses to interview questions from Tal Behar, Precision World Medicine Conference Curtis P. Langlotz, Professor of Radiology, Medicine, and Biomedical Data Science Senior Associate Vice Provost for Research Director, Center for Artificial Intelligence in Medicine & Imaging Senior Fellow, Institute for Human-Centered Artificial Intelligence 1. If you could mandate one […]
Interview Questions for Levi Garraway
Levi Garraway’s responses to interview questions from Tal Behar, Precision World Medicine Conference 1. IO focus: If you could green-light one immuno-oncology combination for a definitive Phase 3 in 2026, which patients benefit, and what one biomarker makes or breaks it? In solid tumors, it seems as though we may be entering an era where […]
Interview Questions for Keith Booher
1. Your talk emphasizes AI-driven workflows for identifying repurposed drugs. Can you share a specific case where your platform identified a treatment for a rare disease, and how it impacted patient outcomes?”
Interview Questions for Mike Snyder, PhD, Stanford
1. Can you describe a project or experience where you integrated data from wearables with multi-omics data? What were the main challenges you faced, and how did you address them?
We have several projects running right
